摘要
目的探究原发性高血压患者行酒石酸美托洛尔片(商品名:倍他乐克)、苯磺酸左旋氨氯地平联合治疗的效果。方法30例原发性高血压1、2级患者,随机分为实验组(18例)与对照组(12例)。实验组应用苯磺酸左旋氨氯地平+倍他乐克治疗,对照组应用苯磺酸左旋氨氯地平治疗。比较两组临床疗效、不良反应发生率及治疗前后血压、心率、动脉硬化指数。结果实验组总有效率94.44%高于对照组的66.67%(P<0.05)。治疗后,实验组收缩压(122.15±4.46)mm Hg(1 mm Hg=0.133 kPa)、舒张压(88.16±4.43)mm Hg、心率(76.75±13.04)次/min均低于对照组的(140.51±7.34)mm Hg、(95.54±6.67)mm Hg、(89.74±9.26)次/min(P<0.05)。治疗后,实验组动脉硬化指数(3.54±0.17)低于对照组的(5.11±1.01)(P<0.05)。实验组不良反应发生率5.56%低于对照组的41.67%(P<0.05)。结论联用倍他乐克、苯磺酸左旋氨氯地平治疗原发性高血压患者的效果确切,可有效调节血压水平和动脉硬化指数,不良反应少,推广可行性显著。
Objective To explore the effect of metoprolol tartrate tablets(trade name:Betaloc)combined with levamlodipine besylate in the treatment of essential hypertension.Methods 30 patients with grade 1 or 2 essential hypertension were randomly divided into an experimental group(18 cases)and a control group(12 cases).The experimental group was treated with levamlodipine besylate and Betaloc,and the control group was treated with levamlodipine besylate.The clinical efficacy,incidence of adverse reactions,blood pressure,heart rate,arteriosclerosis index before and after treatment were compared between the two groups.Results The total effective rate of the experimental group was 94.44%,which was higher than 66.67%of the control group(P<0.05).After treatment,the experimental group had systolic blood pressure of(122.15±4.46)mm Hg(1 mm Hg=0.133 kPa),diastolic blood pressure of(88.16±4.43)mm Hg and heart rate of(76.75±13.04)beats/min,which were lower than(140.51±7.34)mm Hg,(95.54±6.67)mm Hg and(89.74±9.26)beats/min in the control group(P<0.05).After treatment,the arteriosclerosis index of(3.54±0.17)in the experimental group was lower than(5.11±1.01)in the control group(P<0.05).The incidence of adverse reactions in the experimental group was 5.56%,which was lower than 41.67%in the control group(P<0.05).Conclusion The combination of Betaloc and levoamlodipine besylate is effective in the treatment of essential hypertension,and can effectively regulate blood pressure and arteriosclerosis index with less adverse reactions.It can be promoted.
作者
赵广华
ZHAO Guang-hua(Community Health Service Center,Qingmingqiao Street,Liangxi District,Wuxi 214000,China)
出处
《中国现代药物应用》
2024年第4期75-78,共4页
Chinese Journal of Modern Drug Application